Residual Disease

10 registered clinical trials studyying Residual Disease — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease NCT07069595	UNC Lineberger Comprehensive Cancer Center	Phase 2
Recruiting	A Study of Tetrathiomolybdate (TM) Plus Capecitabine NCT06134375	Dartmouth-Hitchcock Medical Center	Phase 1 / Phase 2
Completed	Effective Treatments for Dizziness After BPPV: A Clinical Study NCT06936345	Medipol University	N/A
Active Not Recruiting	Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer NCT04674306	George T. Budd	EARLY_Phase 1
Completed	R0 Resection Rate Between CSP, cEMR and hEMR for 1-2 cm Colorectal SSLs NCT05117879	National Taiwan University Hospital	N/A
Active Not Recruiting	A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer NCT03945721	Massachusetts General Hospital	Phase 1
Active Not Recruiting	Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer NCT03384914	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Completed	Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Period NCT03093207	Universidade Estadual Paulista Júlio de Mesquita Filho	Phase 2 / Phase 3
Unknown	Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases NCT03189576	Tampere University Hospital	N/A
Completed	Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple My NCT02389517	University of Chicago	Phase 2